Alteogen Obtains Canadian Patent for Stable Liquid Formulation of Fusion Protein

[Asia Economy Reporter Geum Bo-ryeong] Alteogen announced on the 3rd that it has acquired a Canadian patent related to 'stable liquid formulation of fusion proteins containing the IgG Fc domain.'

Alteogen stated, "For the original Eylea, formulation patents have been registered at five-year intervals following the substance patent, making it difficult to develop products and enter the market for five years even after the substance patent expires due to the formulation patents. This patent is a formulation patent independently developed by our company, unlike the original Eylea's formulation technology, allowing us to enter the market five years earlier than other competitors."

This content was produced with the assistance of AI translation services.